


**Figure S1. Comparison of editing efficiencies of Cas9-WT and high-fidelity Cas9 variants using gX<sub>19</sub> and gX<sub>20</sub> sgRNAs in HEK293T cells.**


Indel frequencies (measured by targeted deep sequencing) of Cas9-WT and Cas9 variants at five on-target sites with a 5' C or 5' T nucleotide obtained using gX<sub>19</sub> and gX<sub>20</sub> sgRNAs in HEK293T cells. PAM sequences are shown in blue. Error bars, s.e.m. of three biological replicates.




**Figure S2. Comparison of relative indel frequencies of Cas9 variants normalized to that of Cas9-WT in HeLa cells.**

Distributions of relative indel frequencies of Cas9 variants normalized to that of Cas9-WT obtained using HH-X<sub>20</sub>, HH-gX<sub>19</sub> and gX<sub>19</sub> sgRNAs at six endogenous target sites in HeLa cells. Box and whisker plots: center lines show the medians; crosses show the means. Statistical significances were calculated by paired t-test. \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ .


a



b




c



**Figure S3. Comparison of indel frequencies of HH-X<sub>20</sub>, HH-gX<sub>19</sub> and gX<sub>19</sub> sgRNAs in combination with Cas9-WT and Cas9 variants in HEK293T cells.**

(a) HH-X<sub>20</sub> or HH-gX<sub>19</sub> were tested in combination with Cas9-WT and high-fidelity Cas9 variants at five target sites in HEK293T cells. Indel frequencies were measured using targeted deep sequencing. The PAM is shown in blue. Error bars, s.e.m. of three biological replicates. Statistical significances were calculated by unpaired t-test. \*  $P < 0.05$ , \*\*  $P < 0.01$ . (b) Mean indel frequencies  $\pm$  s.e.m. are shown at the five target sites in HEK293T cells. Statistical significances were calculated by paired t-test. \*  $P < 0.05$ . (c) Distributions of relative indel frequencies of eCas9-1.1 and Cas9-HF1 normalized to that of Cas9-WT. Box and whisker plots: center lines show the medians; crosses show the means.



**Figure S4. Specificities of high-fidelity Cas9 variants in combination with HH-X<sub>20</sub> sgRNA in HEK293T cells.**

The HH-X<sub>20</sub> sgRNA expression plasmid was co-transfected with the plasmid encoding Cas9-WT or a Cas9 variant into HEK293T cells. Indel frequencies at on- and off-target sites were measured by targeted deep sequencing. PAM sequences are shown in blue. Mismatched bases are shown in red. The specificity ratio indicates the fold difference between the ratio of on-target indel frequencies to off-target indel frequencies obtained using Cas9 variants and that obtained using Cas9-WT. Error bars, s.e.m. of three biological replicates. Indel frequencies significantly above those of the mock transfected sample are shown by asterisks (\*  $P < 0.05$ , \*\*  $P < 0.01$ ).

**Table S1. Indel frequencies of Cas9-WT, eCas9-1.1 and Cas9-HF1 combined with gX<sub>19</sub> sgRNAs at 26 target sites with an HX<sub>19</sub> sequence.**

gX<sub>19</sub> sgRNAs were co-transfected with Cas9-WT or Cas9 variants into HeLa cells and indel frequencies at 26 sites were measured by targeted deep sequencing. Relative indel frequency is the ratio of indel (%) of Cas9 variant to that of Cas9-WT. Six target sites analyzed in further study with HH-X20 sgRNA are shown in yellow.

gene	sgRNA #	Spacer type	Target sequence (X <sub>20</sub> -PAM)	Indel (%)												Relative Indel frequency, normalized to Cas9-WT	
				Mock			Cas9-WT			eCas9-1.1			Cas9-HF1			eCas9-1.1	Cas9-HF1
				Mean (%)	STDEV	N	Mean (%)	STDEV	N	Mean (%)	STDEV	N	Mean (%)	STDEV	N		
AAVS1	01	CX <sub>19</sub>	CTCCCTCCCAGGATCCTCTCTGG	0.59	0.21	3	71.9	8.1	3	6.7	0.3	3	2.7	0.4	3	0.09	0.04
HBB	02	CX <sub>19</sub>	CTTGCCCCACAGGGCAGTAACGG	0.09	0.07	3	78.2	5.8	3	44.8	7.6	3	16.4	3.1	3	0.57	0.21
HBB	03	CX <sub>19</sub>	CACGTTACCTTGCCCCACAGGG	0.40	0.19	3	75.0	6.4	3	78.2	2.4	3	20.0	1.5	3	1.04	0.27
HBB	04	CX <sub>19</sub>	CCACGTTACCTTGCCCCACAGG	0.09	0.03	3	48.4	11.6	3	33.0	1.2	3	2.2	0.4	3	0.68	0.05
EMX1	C1	CX <sub>19</sub>	CGGCAGAAGCTGGAGGGAAGG	0.05	0.02	2	50.9	5.8	2	8.0	0.3	2	0.1	0.0	2	0.16	0.00
EMX1	C2	CX <sub>19</sub>	CACGAAGCAGGCAATGGGGAGG	0.11	0.08	2	52.1	2.8	2	52.0	5.8	2	19.2	3.6	2	1.00	0.37
EMX1	C3	CX <sub>19</sub>	CGATGCACCTCAATGACTAGG	0.00	0.00	2	69.5	12.6	2	29.9	9.6	2	2.2	0.3	2	0.43	0.03
AAVS1	T1	TX <sub>19</sub>	TGCTTACGATGGAGCCAGAGAG	0.01	0.01	2	66.1	9.8	2	0.0	0.0	2	0.0	0.0	2	0.00	0.00
AAVS1	T2	TX <sub>19</sub>	TAAGCAAACCTTAGAGGTTCTGG	0.00	0.00	2	75.0	6.9	2	10.0	2.9	2	6.2	0.6	2	0.13	0.08
AAVS1	T3	TX <sub>19</sub>	TCTCCTTGCCAGAACCTCTAAGG	0.01	0.01	2	52.6	11.2	2	35.2	17.7	2	10.9	9.1	2	0.67	0.21
HBB	T1	TX <sub>19</sub>	TCTGCCGTTACTGCCCTGTGGGG	0.00	0.00	2	77.8	0.1	2	75.8	4.5	2	70.4	3.5	2	0.97	0.90
HBB	T2	TX <sub>19</sub>	TGGTCTACCTTGAGCCAGAGG	0.02	0.02	2	39.1	16.3	2	30.2	18.0	2	32.4	13.1	2	0.77	0.83
HBB	T3	TX <sub>19</sub>	TCAAAGAACCTCTGGGTCCAAGG	0.02	0.03	2	46.9	15.9	2	0.1	0.1	2	0.0	0.0	2	0.00	0.00
HBB	T4	TX <sub>19</sub>	TCCACTCTGATGCTGTATGGG	0.00	0.00	2	46.8	1.2	2	1.1	0.4	2	0.4	0.1	2	0.02	0.01
EMX1	04	TX <sub>19</sub>	TCTGGAACACACCTTCACTGG	0.01	0.01	3	81.5	1.6	3	80.3	4.2	3	81.5	4.0	3	0.99	1.00
EMX1	05	TX <sub>19</sub>	TGTACTTTGCTCCGGTTCTGG	0.01	0.01	3	84.8	7.9	3	5.1	0.5	3	2.3	0.5	3	0.06	0.03
CCR5	01	TX <sub>19</sub>	TCATCTGTATAAACTGCAAAAAGG	0.10	0.05	3	74.1	5.1	3	1.4	0.6	3	0.2	0.1	3	0.02	0.00
AAVS1	A1	AX <sub>19</sub>	AGATAAGGAATCGCTAACAGG	0.01	0.01	2	73.0	0.0	2	71.9	9.1	2	64.2	12.2	2	0.98	0.88
AAVS1	A2	AX <sub>19</sub>	AGACCCAATATCAGGAGACTAGG	0.02	0.03	2	76.6	3.5	2	80.2	5.7	2	80.5	1.9	2	1.05	1.05
HBB	A1	AX <sub>19</sub>	AAGGTGAACGTGGATGAAGTTGG	0.00	0.00	2	69.9	4.3	2	63.6	1.8	2	65.1	8.4	2	0.91	0.93
EMX1	01	AX <sub>19</sub>	ACCGGAGGACAAAGTACAAACGG	0.02	0.02	3	87.6	0.6	3	88.3	0.8	3	88.9	2.3	3	1.01	1.01
EMX1	02	AX <sub>19</sub>	ATTGCCACGAAGCAGGCAATGG	0.01	0.02	3	83.4	0.8	3	81.9	1.4	3	84.9	4.2	3	0.98	1.02
EMX1	03	AX <sub>19</sub>	ACCACACCTTCACTGGGCCAGG	0.01	0.00	3	80.9	3.3	3	81.1	2.0	3	84.5	3.7	3	1.00	1.04
CCR5	13	AX <sub>19</sub>	AAAGATAGTCATCTGGGGCTGG	0.01	0.01	3	77.2	2.8	3	84.0	2.0	3	83.6	0.9	3	1.09	1.08
CCR5	16	AX <sub>19</sub>	AAAGTGTGATCACTGGGTGGTGG	0.04	0.03	3	87.4	2.5	3	88.7	1.0	3	87.4	2.3	3	1.01	1.00
CCR5	18	AX <sub>19</sub>	AGATGACTATCTTAATGTCTGG	0.00	0.00	3	86.3	3.3	3	84.6	0.8	3	75.5	5.3	3	0.98	0.88
EMX1	N/A	GX <sub>19</sub>	GAGTCCGAGCAGAAGAAGGGG	0.39	0.03	3	91.9	1.1	3	95.8	3.0	3	93.1	0.9	3	1.04	1.01
VEGFA	03	GX <sub>19</sub>	GGTGAGTGAGTGTGCGTGTGG	0.01	0.01	3	95.4	1.9	3	95.9	1.6	3	94.3	2.1	3	1.01	0.99

**Table S2. Comparison of Cas9-WT and Cas9 variants using gX<sub>19</sub> sgRNAs at 26 target sites with an HX<sub>19</sub> sequence.**

Means of indel (%) plotted in Figure 2a and means and medians of relative indel frequency of Cas9 variant to that of Cas9-WT at 26 sites plotted in Figure 2b.

Spacer type	Indel (%)									Relative Indel frequency, normalized to Cas9-WT			
	Cas9-WT			eCas9-1.1			Cas9-HF1			eCas9-1.1		Cas9-HF1	
	Mean (%)	S.E.M	N	Mean (%)	S.E.M	N	Mean (%)	S.E.M	N	Mean	Median	Mean	Median
CX <sub>19</sub>	63.7	4.8	7	36.1	9.5	7	9.0	3.4	7	0.57	0.57	0.14	0.05
TX <sub>19</sub>	64.5	5.3	10	23.9	9.9	10	20.4	9.8	10	0.36	0.10	0.31	0.06
AX <sub>19</sub>	80.3	2.2	9	80.5	2.7	9	79.4	3.1	9	1.00	1.00	0.99	1.01

**Table S3. Comparison of Indel frequencies of HH-X<sub>20</sub>, HH-gX<sub>19</sub> and gX<sub>19</sub> sgRNAs in combination with Cas9-WT and Cas9 variants in HeLa cells**

Indel frequencies (a) and relative indel frequencies of Cas9 variants normalized to that of Cas9-WT (b) at six target sites in HeLa cells.

**a**

gene	Indel (%)								
	Cas9-WT			eCas9-1.1			Cas9-HF1		
	HH-X <sub>20</sub>	HH-gX <sub>19</sub>	gX <sub>19</sub>	HH-X <sub>20</sub>	HH-gX <sub>19</sub>	gX <sub>19</sub>	HH-X <sub>20</sub>	HH-gX <sub>19</sub>	gX <sub>19</sub>
<i>AAVS1-01</i>	80.4	67.6	71.9	74.4	7.1	6.7	73.6	1.7	2.7
<i>HBB-02</i>	67.3	70.4	78.2	64.7	52.1	44.8	52.0	19.3	16.4
<i>HBB-03</i>	81.2	79.3	75.0	85.7	77.3	78.2	78.9	14.9	20.0
<i>HBB-04</i>	49.5	58.2	48.4	56.1	25.8	33.0	48.3	2.4	2.2
<i>CCR5-01</i>	75.4	73.7	74.1	63.5	1.0	1.4	40.4	0.2	0.2
<i>EMX1-05</i>	59.5	72.8	84.8	41.2	1.6	5.1	34.5	1.2	2.3
Median	71.4	71.6	74.6	64.1	16.4	19.8	50.2	2.1	2.5
Mean	68.9	70.3	72.1	64.3	27.5	28.2	54.6	6.6	7.3

**b**

gene	Relative Indel frequency, normalized to Cas9 WT					
	eCas9-1.1			Cas9-HF1		
	HH-X <sub>20</sub>	HH-gX <sub>19</sub>	gX <sub>19</sub>	HH-X <sub>20</sub>	HH-gX <sub>19</sub>	gX <sub>19</sub>
<i>AAVS1-01</i>	0.93	0.10	0.09	0.92	0.03	0.04
<i>HBB-02</i>	0.96	0.74	0.57	0.77	0.27	0.21
<i>HBB-03</i>	1.06	0.98	1.04	0.97	0.19	0.27
<i>HBB-04</i>	1.13	0.44	0.68	0.98	0.04	0.05
<i>CCR5-01</i>	0.84	0.01	0.02	0.54	0.00	0.00
<i>EMX1-05</i>	0.69	0.02	0.06	0.58	0.02	0.03
Median	0.94	0.27	0.33	0.84	0.03	0.04
Mean	0.94	0.38	0.41	0.79	0.09	0.10

**Table S4. Comparison of Indel frequencies of HH-X<sub>20</sub>, HH-gX<sub>19</sub> and gX<sub>19</sub> sgRNAs in combination with Cas9-WT and Cas9 variants in HEK293T cells**

Indel frequencies (a) and relative indel frequencies of Cas9 variants normalized to that of Cas9-WT (b) at five target sites in HEK293T cells.

**a**

gene	Indel (%)								
	Cas9-WT			eCas9-1.1			Cas9-HF1		
	HH-X <sub>20</sub>	HH-gX <sub>19</sub>	gX <sub>19</sub>	HH-X <sub>20</sub>	HH-gX <sub>19</sub>	gX <sub>19</sub>	HH-X <sub>20</sub>	HH-gX <sub>19</sub>	gX <sub>19</sub>
<i>AAVS1-01</i>	77.7	66.1	73.8	54.1	4.1	2.8	78.5	0.7	0.8
<i>HBB-02</i>	51.0	56.6	57.0	36.5	22.1	19.0	23.8	9.5	6.1
<i>HBB-03</i>	61.6	56.7	60.3	50.5	24.9	43.9	44.7	2.6	4.1
<i>HBB-04</i>	27.0	35.3	36.3	15.0	1.7	4.0	13.6	0.5	0.5
<i>CCR5-01</i>	48.5	49.3	33.8	16.4	0.1	0.3	4.7	0.0	0.3
Median	51.0	56.6	57.0	36.5	4.1	4.0	23.8	0.7	0.8
Mean	53.2	52.8	52.2	34.5	10.6	14.0	33.1	2.7	2.4

**b**

gene	Relative Indel frequency, normalized to Cas9 WT					
	eCas9-1.1			Cas9-HF1		
	HH-X <sub>20</sub>	HH-gX <sub>19</sub>	gX <sub>19</sub>	HH-X <sub>20</sub>	HH-gX <sub>19</sub>	gX <sub>19</sub>
<i>AAVS1-01</i>	0.70	0.06	0.04	1.01	0.01	0.01
<i>HBB-02</i>	0.72	0.39	0.33	0.47	0.17	0.11
<i>HBB-03</i>	0.82	0.44	0.73	0.73	0.05	0.07
<i>HBB-04</i>	0.55	0.05	0.11	0.50	0.01	0.01
<i>CCR5-01</i>	0.34	0.00	0.01	0.10	0.00	0.01
Median	0.70	0.06	0.11	0.50	0.01	0.01
Mean	0.62	0.19	0.24	0.56	0.05	0.04